Ocular Therapeutix, Inc.OCULNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +15.41% | -27.59% | -18.14% | -5.71% | -22.43% |
| Gross Profit Growth | +18.17% | -29.83% | -22.88% | -7.89% | -26.47% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +58.62% | +28.31% | +4.08% | +10.14% | +32.68% |
| Weighted Average Shares Diluted Growth | +54.42% | +28.31% | +4.08% | +10.14% | +32.68% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +23.72% | -4.99% | +0.60% | +1.76% | -5.37% |
| Inventory Growth | +31.89% | +27.00% | +19.32% | +45.03% | +17.24% |
| Asset Growth | +81.68% | -24.68% | -12.72% | -16.21% | +76.46% |
| Book Value per Share Growth | +118.15% | -49.20% | -22.18% | -33.40% | +56.39% |
| Debt Growth | -9.12% | +2.44% | +2.74% | +2.51% | +1.56% |
| R&D Expense Growth | +153.10% | +106.69% | +77.01% | +41.30% | +23.94% |
| SG&A Expenses Growth | +47.30% | +25.34% | -5.36% | +27.63% | +20.35% |